November 20th 2024
Benjamin Lockshin, MD, FAAD, discussed combining biologics with topical innovations like tapinarof and roflumilast to address plaque psoriasis treatment gaps.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Genetic Changes in Psoriasis Patients Clear, but Carry Uncertain Consequences
January 19th 2023Over the last few decades, genetic research has opened doors to improve the treatment of immune-mediated conditions like psoriasis, but there are still questions about how these diseases are triggered at the cellular level.
Impact of Data on Generalized Pustular Psoriasis
Aaron S. Farberg, MD, and Jeffrey Crowley, MD, share take-home messages on the impact of the generalized pustular psoriasis study.
Study Limitations in Generalized Pustular Psoriasis
Aaron S. Farberg, MD, and Jeffrey Crowley, MD, discuss study limitations regarding health records in generalized pustular psoriasis and how the number of flares could be underestimated.
Importance of Understanding Data of Generalized Pustular Psoriasis Data
Aaron S. Farberg, MD, and Jeffrey Crowley, MD, discuss the importance of investigating the data on generalized pustular psoriasis, comorbidities of the disease, and commonly used treatments.
Current Treatments for Generalized Pustular Psoriasis
Experts in dermatology review data on various treatment interventions before, during, and after generalized pustular psoriasis flare episodes.
Study Results for Patients With Generalized Pustular Psoriasis
Aaron S. Farberg, MD, and Jeffrey Crowley, MD, examine the results of a study of generalized pustular psoriasis, discussing flares and common signs and symptoms.
Baseline Characteristics of Patients With Generalized Pustular Psoriasis
Aaron S. Farberg, MD, and Jeffrey Crowley, MD, review the demographics of people with generalized pustular psoriasis including age, race, and comorbidities.